ClinicalTrials.gg
Status unknownNCT04581707Updated Jan 19, 2021

Performance and Safety of Joline® Kyphoplasty Single Balloon Catheter Allevo vs. Quattroplasty Double-Balloon Catheter Stop'n GO With BonOs® Inject Bone Cement

An observational study in Vertebral Compression Fracture, sponsored by University Hospital Tuebingen. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-19.

Sponsored by University Hospital Tuebingen · Observational

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
80
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the performance and safety of two balloon kyphoplasty systems (Joline®), the single balloon catheter Allevo and Quattroplasty double balloon catheter Stop'n Go, using BonOs® Inject bone cement for treatment of Vertebral Compression Fractures.

Read the detailed description

Vertebral compression fracture (VCF) is a very common medical problem and describes the collapse of a vertebral body (VB) in the spine. VCF can lead to severe pain, decreased physical function, spinal deformity and in rare cases thoracic or abdominal wall deformities, that can impair pulmonary and gastrointestinal function. A VCF can occur in patients with healthy spines upon severe trauma, in patients suffering from osteoporosis or in patients with metastatic tumors.

Currently available therapy for VCF includes medical management, surgical treatments and vertebral augmentation (VA). Medical management consists of bed rest followed by early mobilization and analgesic medications. Surgical options include spinal stabilization with rods and screws. VA procedures attempt to stabilize the spine and reduce vertical compression by adding material to the spine.

Kyphoplasty is a commonly performed VA procedure. In kyphoplasty, a surgical instrument is used to reduce the collapsed VB towards its original shape. Reduction of the fractured VB is thought to be beneficial since (1) it may reduce anterior directed compressive forces resulting from kyphosis of the spine due to the fracture, and (2) it may reduce some physiologic abnormalities due to kyphosis, such as restrictive lung disease or abdominal compression. After fracture reduction, bone cement is placed in the VB to stabilize the reduction. Fracture reduction follows the orthopedic general principles of fracture repair: reduction and stabilization.

Primary objective of this observational study is to compare the effectiveness of the Quattroplasty double balloon catheter Stop'n GO (Joline®) with the Kyphoplasty single balloon catheter Allevo (Joline®) combined with BonOs® Inject bone cement for use in VCF reduction, to confirm the performance of those two devices and to investigate potential major adverse events associated with the use of the device in patients treated in a controlled setting when used according to the IFU. Secondary objective is to compare the safety of the Quattroplasty double balloon catheter Stop'n GO (Joline®) with the Kyphoplasty single balloon catheter Allevo (Joline®) combined with BonOs® Inject bone cement.

02

Conditions studied

  • Vertebral Compression Fracture

Browse trials for

Keywords

  • Vertebral augmentation
  • Balloon kyphoplasty systems
  • Bone cement
03

In context

Fractures, Compression

50 studies on the registry are indexed under Fractures, Compression; 10 are open to participants now.

This study's planned enrollment of 80 is below the median of 100 across 16 observational studies indexed under Fractures, Compression.

Browse Fractures, Compression studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 490 studies on the registry; 108 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing or patients who have already undergone percutaneous balloon kyphoplasty for treatment of Vertebral Compression Fractures as indicated in the Instructions for use of the investigational devices.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients aged ≥18 years
  • 1-3 painful VCF(s), of which at least 1 meets the following criteria:

    • VCF between T7 and L5
    • Fracture age \<3 months
    • VCF shows hyperintense signal on STIR or T2 sequence MRI.
  • Investigator estimates that target VB(s) is/ are suitable for Quattroplasty double balloon catheter or Kyphoplasty single balloon catheter (e.g. appropriate pedicle diameter, no cortical bone protruding into the spinal canal).
  • Patient has an ODI score of 30% or more.
  • Patient is willing and able to comply with study requirements.
  • Patient signs form.
  • Women who are , surgically sterile or on and agree to remain on contraceptives for the duration of their study participation and agree not to become pregnant during the study.

Exclusion criteria

Exclusion Criteria:

  • Segmental kyphosis of target VB of >30°
  • Pre-existing or clinically unstable neurologic deficit
  • Any physical exam evidence of myelopathy or radiculopathy
  • Not able to walk without assistance prior to fractures
  • Any radiographic evidence of pedicle fracture or interspinous-process widening
  • Spondylolisthesis >grade 1 at target VB(s)
  • History of spine surgery, including prior vertebral augmentation, during the last year
  • Any underlying systemic bone disease other than osteoporosis (e.g. osteomalacia, osteogenesis imperfect, etc.)
  • Irreversible coagulopathy and/or taking peri-operatively warfarin (Coumadin) or other anticoagulant
  • Pregnancy and nursing
  • Pain due to any other condition that requires daily narcotic medication
  • Disabling back pain due to causes other than acute fracture
  • History of intolerance, or allergic reaction to titanium or acrylic compounds
  • Active systemic or local infection at baseline
  • Severe cardiopulmonary disease (e.g. stage IV heart failure, severe )
  • Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g. cancer) or greatly increase the risk of surgery
  • Any evidence of substance abuse
  • The patient is on long-term therapy (steroid dose 30 mg/day for >3 months)
  • The patient is known to be involved in medical litigation including Workmen's compensation.
  • Patient with for MRI including but not limited to patients with contraindications for general anesthesia (surgeon expertise)
  • Patient who is contraindicated for the use of PMMA cement
  • Patients who belong to a vulnerable population or that are not able to sign the form.
  • Patients where the VCF was treated in combination with fusion.
  • Patients with any contraindication according to the IFU
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Kyphoplasty Single Balloon Catheter Allevo

    Device: Kyphoplasty Single Balloon Catheter Allevo

  • Quattroplasty Double Balloon Catheter Stop'n GO

    Device: Quattroplasty Double Balloon Catheter Stop'n GO

Interventions

  • DeviceKyphoplasty Single Balloon Catheter Allevo

    Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement

  • DeviceQuattroplasty Double Balloon Catheter Stop'n GO

    Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement

06

What researchers measure

Primary outcomes

  1. Change in vertebral body height

    Change in vertebral body height

    Time frame: pre-operative, 5 days and 3 months post-operatively

  2. Change in Visual Analog Scale (VAS) of subjective pain

    The Visual Analog Scale (VAS) is a measure for pain intensity. The score of the sclae ranges from 0 for "no pain" to 10 for "worst imaginable pain". Patients will report their pain at baseline and at 2 dedicated periods to assess change in pain intensity.

    Time frame: pre-operation, 5 days and 3 months post-operation

  3. Change in functional disability

    The Oswestry Disability Index (ODI) is used to assess functional disability. The questionnaire consists of 10 items with each item having 6 statements. All scores are summed, then multiplied by two to obtain the index (range from 0 to 100) with higher score indicating greater disability.

    Time frame: pre-operation, 5 days and 3 months post-operation

Secondary outcomes

  1. Safety Outcomes: Occurence of adverse events and complications

    Occurence of adverse events and complications

    Time frame: during procedure, 5 days and 3 months post-operation

07

Study locations

1 of 1 sites recruiting
  • University Hospital for Orthopedics Tuebingen
    Tuebingen, 72076, Germany
    Recruiting
    • Lisanne Exner · Contact
    • Lisanne Exner · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2020 (actual). Primary completion is estimated for Jun 2021, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Oct 9, 2020
StartActual
Mar 1, 2020
Primary completionEst.
Jun 2021
CompletionEst.
Oct 2021
Last update
Jan 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04581707
Responsible party
Lisanne Exner (Medical assistant, University Hospital Tuebingen) — Principal investigator
First posted
Oct 9, 2020
Start date
Mar 1, 2020
Primary completion
Jun 2021 (estimated)
Completion
Oct 2021 (estimated)
Last update
Jan 19, 2021

Study contacts

Lisanne Exner
Contact
Lisanne.Exner@med.uni-tuebingen.de
+4970712986646
Christian Walter, MD
Contact
Christian.Walter@med.uni-tuebingen.de
+4970712986646
Lisanne Exner
principal investigator · University Hopsital for Orthopedics Tuebingen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion